Mesotelioma peritoneal primario diafragmático gigante

  1. Catalina Peña Barturen 1
  2. Amparo Valverde Martínez 1
  3. Javier Varela Recio 1
  4. Dionisio Espinosa Jiménez 1
  5. José Manuel Pacheco García 1
  1. 1 Hospital Universitario Puerta del Mar. Cádiz
Journal:
Cirugía Andaluza

ISSN: 2695-3811,  1130-3212

Year of publication: 2021

Volume: 32

Issue: 2

Pages: 174-177

Type: Article

DOI: 10.37351/2021322.13 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: Cirugía Andaluza

Abstract

Malignant mesothelioma is a rare tumor but is associated with a very high mortality and is considered an aggressive tumor, with an increasing incidence worldwide. It is originated most frequently in the pleural serous membranes, followed by peritoneum, pericardium and tunica vaginalis, assuming the peritoneal mesotheliomas around 10-15% of the cases.CT is the elective diagnosis image but Immunohistochemistry is needed for definitive diagnosis.The management of malignant peritoneal mesothelioma includes a multimodal treatment which involves committee of different specialties.The standard treatment for selected patients with malignant mesothelioma includes Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy while unresectable tumors can be benefitted from the combined treatment of chemotherapy, radiotherapy and immunotherapy .There are some trials ongoing so as to achieve more knowledge of malignant peritoneal mesothelioma.

Bibliographic References

  • Cao S, Jin S et al. Advances in malignant peritoneal mesotelioma. Int J Colorrectal Disease 2015 Jan; 30 (1):1-10 doi 10.1007/s00384-014-2029-1. Epub 2014 Oct 21.
  • Levý M, Boubliková L. et al .Treatment of malignant peritoneal mesothelioma. Klin Onkol 2019 Fall; 32 (5):333-337: doi 10.14735/amko2019333.
  • “Diagnosis and treatment of malignant pleural mesothelioma”. Rodríguez Panadero F. Arch Bronconeumol 2015 Apr;51(4):177-84. doi:10.1016/j.arbres.2014.06.005 Epub 2014 Jul 22.
  • Broeckx G, Pauwels P. “Malignant peritoneal mesothelioma: a review.” Transl Lung Cancer Res 2018;7(5):537-542. doi: 10.21037/tlcr.2018.10.04
  • Tandon RT, Jimenez-Cortez Y, Taub R, et al. “Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.” Arch Pathol Lab Med 2018;142:236-42
  • Kittaneh M, Berkelhammer C. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. J Transl Med 2018;16:194.
  • Helm JH,Miura JT, Glenn JA, et al. “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis”. Ann Surg Oncol 2015;22:1686-93.
  • Grosso F, Steele N, Novello S, et al. “Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial”. J Clin Oncol 2017;35:3591-600. 33.
  • Zalcman G, Mazieres J, Margery J, et al. “Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.” Lancet 2016;387:1405-14.
Data source: Dialnet